Mizuho lowered the firm’s price target on Glaukos (GKOS) to $175 from $200 and keeps an Outperform rating on the shares as part of a Q1 preview for the medical devices and diagnostics group. The firm views tariffs, China exposure, and the latest procedure outlook as the key themes heading into the quarter. It cut numbers preemptively.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos price target lowered to $165 from $180 at Piper Sandler
- Glaukos price target lowered to $114 from $155 at BTIG
- Glaukos price target lowered to $140 from $185 at Truist
- Glaukos Highlights Strategic Focus in 2024 Presentation
- Glaukos, RadiusXR collaborate with Topcon Healthcare on vision testing platform